TY - JOUR
T1 - Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
AU - for the M. T. N.-020/ASPIRE Study Team
AU - Husnik, Marla J.
AU - Brown, Elizabeth R.
AU - Dadabhai, Sufia S.
AU - Gaffoor, Zakir
AU - Jeenarain, Nitesha
AU - Kiweewa, Flavia Matovu
AU - Livant, Edward
AU - Mansoor, Leila E.
AU - Mirembe, Brenda Gati
AU - Palanee-Phillips, Thesla
AU - Singh, Devika
AU - Siva, Samantha
AU - Soto-Torres, Lydia
AU - van der Straten, Ariane
AU - Baeten, Jared M.
AU - Brown, Elizabeth
AU - Schwartz, Katie
AU - Makanani, Bonus
AU - Martinson, Francis
AU - Bekker, Linda Gail
AU - Govender, Vaneshree
AU - Naidoo, Logashvari
AU - Pather, Arendevi
AU - Mhlanga, Felix
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/9
Y1 - 2021/9
N2 - Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.
AB - Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.
KW - Adherence
KW - Correlates
KW - Dapivirine
KW - HIV-1 prevention
KW - Vaginal ring
UR - http://www.scopus.com/inward/record.url?scp=85113419376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113419376&partnerID=8YFLogxK
U2 - 10.1007/s10461-021-03231-x
DO - 10.1007/s10461-021-03231-x
M3 - Article
C2 - 34117592
AN - SCOPUS:85113419376
SN - 1090-7165
VL - 25
SP - 2801
EP - 2814
JO - AIDS and behavior
JF - AIDS and behavior
IS - 9
ER -